{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:17:21Z","timestamp":1793146641438,"version":"4.5.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 82072833 and No. 82272864"],"award-info":[{"award-number":["No. 82072833 and No. 82272864"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 82072833 and No. 82272864"],"award-info":[{"award-number":["No. 82072833 and No. 82272864"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 82072833 and No. 82272864"],"award-info":[{"award-number":["No. 82072833 and No. 82272864"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 82072833 and No. 82272864"],"award-info":[{"award-number":["No. 82072833 and No. 82272864"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 82072833 and No. 82272864"],"award-info":[{"award-number":["No. 82072833 and No. 82272864"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 82072833 and No. 82272864"],"award-info":[{"award-number":["No. 82072833 and No. 82272864"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Capital\u2019s Funds for Health Improvement and Research","award":["No. 2024-2-2059"],"award-info":[{"award-number":["No. 2024-2-2059"]}]},{"name":"Capital\u2019s Funds for Health Improvement and Research","award":["No. 2024-2-2059"],"award-info":[{"award-number":["No. 2024-2-2059"]}]},{"name":"Capital\u2019s Funds for Health Improvement and Research","award":["No. 2024-2-2059"],"award-info":[{"award-number":["No. 2024-2-2059"]}]},{"name":"Capital\u2019s Funds for Health Improvement and Research","award":["No. 2024-2-2059"],"award-info":[{"award-number":["No. 2024-2-2059"]}]},{"name":"Capital\u2019s Funds for Health Improvement and Research","award":["No. 2024-2-2059"],"award-info":[{"award-number":["No. 2024-2-2059"]}]},{"name":"Capital\u2019s Funds for Health Improvement and Research","award":["No. 2024-2-2059"],"award-info":[{"award-number":["No. 2024-2-2059"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-14846-x","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T10:54:11Z","timestamp":1759229651000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Adverse events associated with Lutetium-177-PSMA-617 (Pluvicto\u00ae) in advanced prostate cancer: a disproportionality analysis based on the fda\u2019s adverse event reporting system (FAERS)"],"prefix":"10.1186","volume":"25","author":[{"given":"Yongchen","family":"Jin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yishan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingshuai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxuan","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Ping","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nianzeng","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,30]]},"reference":[{"key":"14846_CR1","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17\u201348.","journal-title":"CA Cancer J Clin"},{"key":"14846_CR2","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, et al. Lutetium-177-PSMA-617 for metastatic Castration-Resistant prostate cancer. N Engl J Med. 2021;385:1091\u2013103.","journal-title":"N Engl J Med"},{"key":"14846_CR3","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1038\/pcan.2014.35","volume":"17","author":"A Patrikidou","year":"2014","unstructured":"Patrikidou A, et al. Who dies from prostate cancer? Prostate Cancer Prostatic Dis. 2014;17:348\u201352.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"14846_CR4","doi-asserted-by":"crossref","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Stat 2022 CA: Cancer J Clinicians. 2022;72(1):7\u201333.","DOI":"10.3322\/caac.21708"},{"key":"14846_CR5","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","volume":"367","author":"HI Scher","year":"2012","unstructured":"Scher HI, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187\u201397.","journal-title":"N Engl J Med"},{"key":"14846_CR6","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/S1470-2045(14)71205-7","volume":"16","author":"CJ Ryan","year":"2015","unstructured":"Ryan CJ, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16:152\u201360.","journal-title":"Lancet Oncol"},{"key":"14846_CR7","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/S1470-2045(12)70379-0","volume":"13","author":"K Fizazi","year":"2012","unstructured":"Fizazi K, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012;13:983\u201392.","journal-title":"Lancet Oncol"},{"key":"14846_CR8","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/S0140-6736(21)02437-5","volume":"399","author":"G Attard","year":"2022","unstructured":"Attard G, et al. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. Lancet (London England). 2022;399:447\u201360.","journal-title":"Lancet (London England)"},{"key":"14846_CR9","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1056\/NEJMoa1405095","volume":"371","author":"TM Beer","year":"2014","unstructured":"Beer TM, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371:424\u201333.","journal-title":"N Engl J Med"},{"key":"14846_CR10","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1002\/cncr.32733","volume":"126","author":"Z Zhai","year":"2020","unstructured":"Zhai Z, et al. Incidence and disease burden of prostate cancer from 1990 to 2017: results from the global burden of disease study 2017. Cancer. 2020;126:1969\u201378.","journal-title":"Cancer"},{"key":"14846_CR11","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1002\/(SICI)1097-0142(19980601)82:11<2256::AID-CNCR22>3.0.CO;2-S","volume":"82","author":"DG Bostwick","year":"1998","unstructured":"Bostwick DG, Pacelli A, Blute M, Roche P, Murphy GP. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer. 1998;82:2256\u201361.","journal-title":"Cancer"},{"key":"14846_CR12","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1002\/pros.21241","volume":"71","author":"S Minner","year":"2011","unstructured":"Minner S, et al. High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer. Prostate. 2011;71:281\u20138.","journal-title":"Prostate"},{"key":"14846_CR13","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1146\/annurev-med-062117-073027","volume":"70","author":"SP Rowe","year":"2019","unstructured":"Rowe SP, Gorin MA, Pomper MG. Imaging of Prostate-Specific membrane antigen with Small-Molecule PET radiotracers: from the bench to advanced clinical applications. Annu Rev Med. 2019;70:461\u201377.","journal-title":"Annu Rev Med"},{"key":"14846_CR14","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.2967\/jnumed.115.161299","volume":"56","author":"A Afshar-Oromieh","year":"2015","unstructured":"Afshar-Oromieh A, et al. The theranostic PSMA ligand PSMA-617 in the diagnosis of prostate cancer by PET\/CT: biodistribution in humans, radiation dosimetry, and first evaluation of tumor lesions. J Nuclear Medicine: Official Publication Soc Nuclear Med. 2015;56:1697\u2013705.","journal-title":"J Nuclear Medicine: Official Publication Soc Nuclear Med"},{"key":"14846_CR15","doi-asserted-by":"publisher","first-page":"517","DOI":"10.2967\/jnumed.118.219352","volume":"60","author":"J Violet","year":"2019","unstructured":"Violet J, et al. Dosimetry of 177Lu-PSMA-617 in metastatic Castration-Resistant prostate cancer: correlations between pretherapeutic imaging and Whole-Body tumor dosimetry with treatment outcomes. J Nuclear Medicine: Official Publication Soc Nuclear Med. 2019;60:517\u201323.","journal-title":"J Nuclear Medicine: Official Publication Soc Nuclear Med"},{"key":"14846_CR16","doi-asserted-by":"crossref","unstructured":"Hennrich U, Eder M. [177Lu]Lu-PSMA-617 (PluvictoTM): The First FDA-Approved Radiotherapeutical for Treatment of Prostate Cancer. Pharmaceuticals (Basel Switzerland). 2022;15(10):1292.","DOI":"10.3390\/ph15101292"},{"key":"14846_CR17","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s40264-021-01142-3","volume":"45","author":"D Croteau","year":"2022","unstructured":"Croteau D, et al. Sources of evidence triggering and supporting Safety-Related labeling changes: A 10-Year longitudinal assessment of 22 new molecular entities approved in 2008 by the US food and drug administration. Drug Saf. 2022;45:169\u201380.","journal-title":"Drug Saf"},{"key":"14846_CR18","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.therap.2019.01.006","volume":"74","author":"JL Faillie","year":"2019","unstructured":"Faillie JL. Case-non-case studies: principle, methods, bias and interpretation. Therapie. 2019;74:225\u201332.","journal-title":"Therapie"},{"key":"14846_CR19","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1002\/pds.4446","volume":"27","author":"WN Insani","year":"2018","unstructured":"Insani WN, Pacurariu AC, Mantel-Teeuwisse AK, Gross-Martirosyan L. Characteristics of drugs safety signals that predict safety related product information update. Pharmacoepidemiol Drug Saf. 2018;27:789\u201396.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"14846_CR20","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12916-016-0553-2","volume":"14","author":"IJ Onakpoya","year":"2016","unstructured":"Onakpoya IJ, Heneghan CJ, Aronson JK. Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature. BMC Med. 2016;14:10.","journal-title":"BMC Med"},{"key":"14846_CR21","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s40264-018-00792-0","volume":"42","author":"M Pham","year":"2019","unstructured":"Pham M, Cheng F, Ramachandran K. A comparison study of algorithms to detect Drug-Adverse event associations: frequentist, bayesian, and Machine-Learning approaches. Drug Saf. 2019;42:743\u201350.","journal-title":"Drug Saf"},{"key":"14846_CR22","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1001\/jamainternmed.2019.3066","volume":"179","author":"N Tau","year":"2019","unstructured":"Tau N, et al. Association between data sources and US food and drug administration drug safety communications. JAMA Intern Med. 2019;179:1590\u20132.","journal-title":"JAMA Intern Med"},{"key":"14846_CR23","doi-asserted-by":"publisher","first-page":"616505","DOI":"10.3389\/fphar.2021.616505","volume":"12","author":"C Chen","year":"2021","unstructured":"Chen C, et al. Cardiotoxicity induced by immune checkpoint inhibitors: A pharmacovigilance study from 2014 to 2019 based on FAERS. Front Pharmacol. 2021;12:616505.","journal-title":"Front Pharmacol"},{"key":"14846_CR24","doi-asserted-by":"publisher","first-page":"591","DOI":"10.2165\/00002018-200427080-00010","volume":"27","author":"EG Brown","year":"2004","unstructured":"Brown EG. Using meddra: implications for risk management. Drug Saf. 2004;27:591\u2013602.","journal-title":"Drug Saf"},{"key":"14846_CR25","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","volume":"13","author":"KJ Rothman","year":"2004","unstructured":"Rothman KJ, Lanes S, Sacks ST. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf. 2004;13:519\u201323.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"14846_CR26","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","volume":"10","author":"SJ Evans","year":"2001","unstructured":"Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf. 2001;10:483\u20136.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"14846_CR27","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","volume":"54","author":"A Bate","year":"1998","unstructured":"Bate A, et al. A bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol. 1998;54:315\u201321.","journal-title":"Eur J Clin Pharmacol"},{"key":"14846_CR28","doi-asserted-by":"publisher","unstructured":"Zhao K, Xiao S, Zhao Y, Tu C. Real-world safety of deucravacitinib: insights from the Food and Drug Administration Adverse Event Reporting System. Int J Clin Pharm. 2025. https:\/\/doi.org\/10.1007\/s11096-025-01896-1.","DOI":"10.1007\/s11096-025-01896-1"},{"key":"14846_CR29","doi-asserted-by":"publisher","first-page":"1458438","DOI":"10.3389\/fphar.2024.1458438","volume":"15","author":"K Zhao","year":"2024","unstructured":"Zhao K, Zhao Y, Xiao S, Tu C. Assessing the real-world safety of tralokinumab for atopic dermatitis: insights from a comprehensive analysis of FAERS data. Front Pharmacol. 2024;15:1458438.","journal-title":"Front Pharmacol"},{"key":"14846_CR30","doi-asserted-by":"crossref","unstructured":"Yu RJ, Krantz MS, Phillips EJ, Stone CA. Emerging Causes of Drug-Induced Anaphylaxis: A Review of Anaphylaxis-Associated Reports in the FDA Adverse Event Reporting System (FAERS). J Allergy Clin Immunol Pract. 2021;9(2):819\u2013829.e2.","DOI":"10.1016\/j.jaip.2020.09.021"},{"key":"14846_CR31","doi-asserted-by":"crossref","unstructured":"Zhao K, Xiao S, Zhao Y, Tu C. Comprehensive post-marketing safety analysis of tildrakizumab: insights from the FDA adverse event reporting system. Exp Opin Drug Saf. 2025:17:1\u20138.","DOI":"10.1080\/14740338.2025.2520422"},{"key":"14846_CR32","doi-asserted-by":"crossref","unstructured":"van Puijenbroek EP, et al. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf. 2002;11(1):3\u201310.","DOI":"10.1002\/pds.668"},{"key":"14846_CR33","unstructured":"E. M. Agency. ICH Clinical safety data management: definitions and standards for expedited reportinG E2A. chap. B. Serious Adverse Event or Adverse Drug Reaction; 1994."},{"key":"14846_CR34","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.eururo.2024.04.010","volume":"86","author":"D Tilki","year":"2024","unstructured":"Tilki D, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on prostate cancer. Part II-2024 update: treatment of relapsing and metastatic prostate cancer. Eur Urol. 2024;86:164\u201382.","journal-title":"Eur Urol"},{"key":"14846_CR35","doi-asserted-by":"crossref","unstructured":"Groener D, et al. Impact of [177Lu]Lu-PSMA-617 Radioligand Therapy on Reference Organ Uptake Assessed by [68Ga]Ga-PSMA-11-PET\/CT. Cancers. 2023;15(15):3878.","DOI":"10.3390\/cancers15153878"},{"key":"14846_CR36","doi-asserted-by":"crossref","unstructured":"Mehrens D, et al. Cost-Effectiveness Analysis of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer. J Natl Compr Cancer Network: JNCCN. 2023;21(1):43\u201350.e2.","DOI":"10.6004\/jnccn.2022.7070"},{"key":"14846_CR37","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1080\/14737140.2023.2213892","volume":"23","author":"K Patell","year":"2023","unstructured":"Patell K, et al. Lutetium-177 PSMA for the treatment of metastatic castrate resistant prostate cancer: a systematic review. Expert Rev Anticancer Ther. 2023;23:731\u201344.","journal-title":"Expert Rev Anticancer Ther"},{"key":"14846_CR38","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1093\/oncolo\/oyac279","volume":"28","author":"B Ramnaraign","year":"2023","unstructured":"Ramnaraign B, Sartor O. PSMA-Targeted radiopharmaceuticals in prostate cancer: current data and new trials. Oncologist. 2023;28:392\u2013401.","journal-title":"Oncologist"},{"key":"14846_CR39","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.eururo.2022.05.025","volume":"83","author":"H Sch\u00e4fer","year":"2023","unstructured":"Sch\u00e4fer H, et al. Extensive 177Lu-PSMA radioligand therapy can lead to radiation nephropathy with a renal thrombotic Microangiopathy-like picture. Eur Urol. 2023;83:385\u201390.","journal-title":"Eur Urol"},{"key":"14846_CR40","doi-asserted-by":"publisher","first-page":"102699","DOI":"10.1016\/j.ctrv.2024.102699","volume":"125","author":"EF Giunta","year":"2024","unstructured":"Giunta EF, et al. 177Lu-PSMA therapy in metastatic prostate cancer: an updated review of prognostic and predictive biomarkers. Cancer Treat Rev. 2024;125:102699.","journal-title":"Cancer Treat Rev"},{"key":"14846_CR41","doi-asserted-by":"publisher","first-page":"25712","DOI":"10.1038\/s41598-024-77889-3","volume":"14","author":"S Wu","year":"2024","unstructured":"Wu S, Hu W, Chen M, Xiao X, Liu R. A real-world pharmacovigilance study of FDA adverse event reporting system events for Lutetium-177-PSMA-617. Sci Rep. 2024;14:25712.","journal-title":"Sci Rep"},{"key":"14846_CR42","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","volume":"397","author":"MS Hofman","year":"2021","unstructured":"Hofman MS, et al. [177Lu]Lu-PSMA-617 versus Cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet (London England). 2021;397:797\u2013804.","journal-title":"Lancet (London England)"},{"key":"14846_CR43","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/S1470-2045(18)30198-0","volume":"19","author":"MS Hofman","year":"2018","unstructured":"Hofman MS, et al. [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol. 2018;19:825\u201333.","journal-title":"Lancet Oncol"},{"key":"14846_CR44","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1002\/cpt.2951","volume":"114","author":"C Khouri","year":"2023","unstructured":"Khouri C, Fusaroli M, Salvo F, Raschi E. Interpretation of pharmacovigilance disproportionality analyses. Clin Pharmacol Ther. 2023;114:745\u20136.","journal-title":"Clin Pharmacol Ther"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14846-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-14846-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14846-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T23:30:10Z","timestamp":1759275010000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-14846-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["14846"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-14846-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6084374\/v1","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,30]]},"assertion":[{"value":"22 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Institutional review board approval was waived for this study because FAERS is a public anonymized database.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Data that support the findings of this study is obtained from the FDA Adverse Event Reporting System (FAERS) database that was provided by the FDA. No individual patient consent was required for the publication of this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1470"}}